

Who accesses PrEP?

An analysis of baseline data in the PROUD pilot

David Dolling, Monica Desai, Vanessa Apea, Nicola Mackie, Alan McOwan, Elaney Youssef, Christine Bowman, Charles Lacey, Gabriel Schembri, Richard Gilson, Ann Sullivan, Iain Reeves, Jake Bayley, Julie Fox, Steve Taylor, Saye Khoo, Mitzy Gafos, Anthony Nardone, Noel Gill, David Dunn, Sheena McCormack
on behalf of the PROUD study

Overview

- Background
- Overview of the PROUD pilot study
- Baseline results
 - Who is enrolling?
 - Sexual risk
- Conclusions

Background

- FDA approve Truvada as PrEP July 2012



- Proven biological efficacy of PrEP, but 'real world' effectiveness unknown
- PrEP only available in UK through PROUD pilot study

The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK

S McCormack MSc FRCP*, S Fidler PhD MRCP† and M Fisher MBBS FRCP‡

*MRC Clinical Trials Unit, London; †Department of Medicine, Imperial College London, London; ‡Department of HIV/Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

PROUD Pilot Study

PRe-exposure **O**ption for reducing
HIV in the **UK**: an open-label
randomisation to immediate or
Deferred daily Truvada for HIV
negative gay men

PROUD Pilot

MSM reporting UAI
Willing to take a pill now or in 12M



Randomize 500 HIV negative eligible MSM
(exclude if on treatment for hepB)

Risk reduction includes
Truvada **NOW**

Risk reduction includes
Truvada **in 12M**



Follow **3 monthly** for up to 24 months

Main endpoints: recruitment and retention

494 enrolled as of 17th March 2014

Who is enrolling?

Data based on 494 enrolled, 443 baseline CRFs

Key demographics at baseline

		Number (N=439- 443)	Percentage (%)
Age	Median	35.5	IQR: 29.4- 42.3
Ethnicity	White	349	80%
	Black	14	4%
	S Asian	27	6%
	Other	48	10%
Maximum education	University degree or above	258	59%
	A-levels/equivalent	73	17%
	No qualifications	11	3%
	Other	97	23%
Enrolled as partners		17 (+1 triplet)	


Sexual risk at baseline

	Median	IQR
Sexual partners		
Total	10	4-20
Condomless receptive anal sex	2	1-5
Condomless insertive anal sex	3	1-6
	Number (N=440)	Percentage (%)
Partnerships		
In ongoing partnership	206	47%
Living with partner	138	31%

Reasons for no condoms

	Frequency of responses (N=1362)	Percentage of cases (%)
Reasons for no condom		
It's much more enjoyable without a condom	289	66%
I don't like using condoms	222	51%
He doesn't like using condoms	143	33%
Condoms weren't discussed	116	27%
Under the influence of drugs	102	23%
I don't consider myself at risk of HIV	98	22%
Under the influence of alcohol	94	22%
I was only dipping	81	19%
We don't use condoms with each other, but do with other partners	74	17%
Other less frequent reasons	143	33%


Partner serostatus at last anal sex



PEP use

	Number (N=420)	Percentage (%)
PEP use		
At least once in past 12 months	177	40%
>once in past 12 months	87	21%

Sexually transmitted infections



MRC | Medical Research Council
Comparison data: 1. Public Health England: STI data tables for England 2012; 2. Centers for Disease Control 2010 STDs in Men who have sex with men <http://www.cdc.gov/std/stats10/msm.htm>

Recreational drug use

- 322/434 (74%) report use of recreational drugs in past 12 months

Drug	Frequency of reports (N=957)	Percentage of cases
Poppers (amyl nitrate)	213	67%
Viagra	182	57%
Mephadrone	158	49%
GHB (liquid ecstasy)	136	43%
Cannabis	102	32%
Cocaine (coke)	113	35%
Ecstasy	84	26%
Crystal meth (methamphetamine)	78	24%

Conclusions

- Public health benefit of PrEP will depend on effective targeting
- Pilot study recruiting gay or other MSM at high risk of HIV infection
- Trial Steering Committee have encouraged scale up to a full trial as highly relevant for public health policy

Acknowledgements (1)



Study participants

MRC CTU at UCL

David Dolling, David Dunn, Mitzzy Gafos, Gemma Wood, Liz Brodnicki, Yolanda Collaco-Moraes, Sarah Banbury, Brendan Mauger, Yinka Sowunmi, Christina Chung, Sheena McCormack

HIV & STI Dept, PHE

Anthony Nardone, Noel Gill, Sarika Desai, GUMCAD team, HIV team

Clinics

Vanessa Apea (Barts Health NHS Trust), Nicola Mackie (St Mary's Hospital), Alan McOwan (56 Dean Street), Amanda Clarke (Claude Nichol Centre), Christine Bowman (Sheffield Teaching Hospitals NHS Foundation Trust), Charles Lacey (York Hospitals NHS Foundation Trust), Gabriel Schembri (Manchester Centre for Sexual Health), Richard Gilson (The Mortimer Market Centre), Ann Sullivan (John Hunter Clinic for Sexual Health), Iain Reeves (Homerton University Hospital NHS Foundation Trust), Michael Brady (Kings College Hospital NHS Foundation Trust), Julie Fox (Guy's and St Thomas's NHS Foundation Trust), Steve Taylor (Heart of England NHS Foundation Trust), Saye Khoo (University of Liverpool)

Acknowledgements (2)



Trial Steering Committee

Independent members: Mike Adler (Co-Chair), Gus Cairns (Co-Chair), Dan Clutterbuck, Rob Cookson, Claire Foreman, Stephen Nicholson, Tariq Sadiq, Matthew Williams

Investigator members: Brian Gazzard, Noel Gill, Anne Johnson, Sheena McCormack, Andrew Phillips

Community Engagement Group

Alan McOwan (Lead), Yusef Azad (NAT), Anthony Bains, Gus Cairns (NAM), Rob Cookson (LGF), Tom Doyle (Mesmac), Mitzy Gafos (MRC CTU at UCL), Justin Harbottle (THT), Matthew Hodson (GMFA), Cary James (THT), Ben McClelland (THT), Sheena McCormack (MRC CTU at UCL), Francesa McNeil (PHE), Roger Pebody (NAM), Annabelle South (MRC CTU at UCL)

Gilead

Jim Rooney, Rich Clarke, Matt Bosse, Murad Ruf

Academia:

Will Nutland (LSHTM)

Social media:

Darren Clapich (Grindr), Simon Johnson (Gaydar)

Press:

David Rowlands (Baseline), Robert Fieldhouse (Baseline), Chris O'Connor (Baseline), Patrick Cash (QX)